中晚期肝細(xì)胞癌的局部治療聯(lián)合系統(tǒng)治療研究進(jìn)展

摘要：我國大部分肝細(xì)胞癌患者就診時(shí)已處于疾病的中晚期階段，單一治療方案客觀緩解率較低，而聯(lián)合治療明顯提高了中晚期肝細(xì)胞癌患者的客觀緩解率，延長了患者的生存期。本文就近年來中晚期肝細(xì)胞癌局部治療聯(lián)合系統(tǒng)治療的最新研究進(jìn)展進(jìn)行詳細(xì)闡述。關(guān)鍵詞：癌， 肝細(xì)胞； 化學(xué)栓塞， 治療性； 分子靶向治療基金項(xiàng)目：江蘇省衛(wèi)健委重點(diǎn)科研項(xiàng)目（ZD2021061）

Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma

CAO Bailu， AI Min， HUANG Ping， YANG Yongfeng. （Department of Hepatology， Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital， Nanjing 210003， China）

Corresponding author：YANG Yongfeng， yyf1979@163.com （ORCID：0000-0002-0942-4833）

Abstract：Most patients with hepatocellular carcinoma （HCC） have reached the advanced stage at the time of diagnosis in China， and a single treatment regimen tends to have a low objective response rate （ORR）， while combined therapy can significantly increase the ORR of patients with advanced HCC and prolong their survival time. The article elaborates on the latest research advances in the efficacy of local treatment combined with systemic therapy for advanced HCC.

Key words：Carcinoma， Hepatocellular； Chemoembolization， Therapeutic； Molecular Targeted Therapy

Research funding：Key Program of Jiangsu Commision of Health （ZD2021061）

肝細(xì)胞癌（HCC）是全世界最常見的惡性腫瘤之一，每年死亡率位居第2位，僅次于胰腺癌［1］。（剩余14111字）